Anti-CD257 (BAFF) [Tabalumab]

TNFSF20; B-cell activating factor; Tumor Necrosis Factor Superfamily Member 13b; BAFF; Tumor Necrosis Factor (Ligand) Superfamily, Member 13b; Dendritic Cell-Derived TNF-Like Molecule; TALL-1; TALL1; ZTNF4; BLYS; Tumor Necrosis Factor (Ligand) Superfamily, Member 20; Tumor Necrosis Factor Ligand Superfamily Member 13B; TNF- And APOL-Related Leukocyte Expressed Ligand 1; TNF And ApoL-Related Leukocyte Expressed Ligand 1; Tumor Necrosis Factor-Like Protein ZTNF4; TNF Homolog That Activates Apoptosis; Tumor Necrosis Factor Ligand 7A; ApoL Related Ligand TALL-1; B-Lymphocyte Stimulator; B Lymphocyte Stimulator; CD257 Antigen; Delta4 BAFF; Delta BAFF; TNLG7A; THANK; DTL; LY 2127399; LY2127399

Monoclonal antibodies were generated by immunizing human immunoglobulin transgenic mice with soluble human BAFF (amino acids 133–285) . Eight mice producing serum antibody titers to human BAFF were injected intravenously with 10 μg human BAFF in phosphate buffered saline. The spleen was harvested 3 days later from each mouse and fused with myeloma cells. 20 Hybridomas were tested for specific binding to human BAFF and to make sure they were expressing human immunoglobulin heavy and light chains by enzyme-linked immunosorbent assay (ELISA) . The hybridoma producing the antibody that eventually became tabalumab was a human IgG1 isotype. The antibody was then engineered to a human IgG4 isotype for complete neutralization of BAFF without depletion of BAFF-expressing cells.